



10 December 2018

ASX ANNOUNCEMENT

Early Surveillance with L-Dex® Reduces Incidence, Severity and Cost

Brisbane, Australia and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced the publication in *Cancer* of a landmark study out of Macquarie University. *Cancer* is an international journal of the American Cancer Society. The society prides itself on content that is "the latest clinical research findings."

The study conducted by Louise Koelmeyer, Lymphoedema Program Manager, ALERT – Australian Lymphoedema Education, Research & Treatment, found that the use of BIS as part of an early prospective surveillance model of care results in significantly earlier detection of lymphoedema over time and that earlier detection of lymphoedema will lead to lower health care costs.

This large retrospective analysis of a busy practice study examined the outcomes of patients who were followed in either (a) early surveillance group or (b) traditional referral group. The early surveillance group included patients prospectively followed with L-Dex, from a pre-operative baseline or within 90 days of their surgery. The traditional referral group consists of patients who were referred to the practice >90 days from the time of surgery.

The results indicate that women who underwent early surveillance received lymphoedema care almost 2 years earlier than women in the traditional referral group. The early surveillance group had a significantly lower incidence of clinical lymphoedema than the traditional referral group, and those who were diagnosed in the early surveillance group had significantly less severe lymphoedema.

"My vision is that all women diagnosed with breast cancer will have access to a prospective surveillance model of care which include BIS technology, education and early intervention", stated Ms Koelmeyer.

"This is an important piece of work demonstrating the long-term value of a prospective model of care using ImpediMed's L-Dex technology to improve patient outcomes and reduce the cost of care." commented Richard Carreon, Managing Director and CEO of ImpediMed.

"This landmark study adds to the growing body of clinical evidence and will significantly strengthen our case to the NCCN and private payors." Carreon added

<https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnrcr.31873>

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.